Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair

The median survival for patients with locally advanced pancreatic cancer treated with gemcitabine and radiation is approximately one year. To develop improved treatment, we have combined a Chk1/2 targeted agent, AZD7762, currently in Phase I clinical trials, with gemcitabine and ionizing radiation i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Morgan, Meredith A., Parsels, Leslie A., Zha, Lili, Parsels, Joshua D., Davis, Mary A., Hassan, Maria C., Arumugarajah, Sankari, Hylander-Gans, Linda, Morosini, Deborah, Simeone, Diane M., Canman, Christine E., Normolle, Daniel P., Zabludoff, Sonya D., Maybaum, Jonathan, Lawrence, Theodore S.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2889008/
https://ncbi.nlm.nih.gov/pubmed/20501833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3573
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars